吉非替尼联合中药治疗局部晚期非小细胞肺癌疗效观察被引量：17

下载PDF

导出

摘要目的观察吉非替尼联合中药治疗晚期局部非小细胞肺癌的临床效果与安全性。方法将206例晚期非小细胞肺癌患者随机平均分为2组,对照组103例给予吉非替尼250 mg口服,每日1次,观察组103例在对照组治疗基础上给予中药攻补兼施方案治疗,在治疗16周后统计近期疗效,记录患者无进展生存期与毒副反应以及治疗前后KPS生存质量评分。结果观察组治疗16周后的完全缓解率及临床总有效率均明显高于对照组(P均<0.05),患者无进展生存期明显长于对照组(P<0.05),治疗后KPS评分明显高于对照组及治疗前(P均<0.05);观察组腹泻、恶心呕吐不良反应发生率明显低于对照组(P均<0.05)。结论吉非替尼联合攻补兼施中药治疗晚期非小细胞肺癌可以有效提高治疗有效性,延长患者的无进展生存期,并减少毒副反应。

作者李新泽李亚博

机构地区河北省邢台市第五医院北京东直门医院

出处《现代中西医结合杂志》 CAS 2017年第18期2028-2030,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine

关键词吉非替尼中药攻补兼施局部晚期非小细胞肺癌

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

12015美国国家综合癌症网络(NCCN)指南:肺癌的全身治疗[J].中国全科医学,2015,18(18):2126-2126. 被引量：18
2许建萍,张湘茹.吉非替尼治疗晚期肺腺癌的疗效和毒副作用[J].肿瘤防治研究,2009,36(1):60-62. 被引量：13
3章卫华,叶敏,周荣伟,孙坚.化疗联合CDA-Ⅱ治疗晚期复治非小细胞肺癌的疗效分析[J].重庆医学,2014,43(32):4361-4362. 被引量：6
4周欣,李晓琴,王秀丽,顾国民,刘春玲.吉非替尼获得性耐药的非小细胞肺癌患者临床特点[J].中国癌症杂志,2015,25(3):222-230. 被引量：10
5侯仰韶.从乏证可辨型肺癌的中医治则谈肺癌的同病类证类治[J].中医杂志,2015,56(6):531-533. 被引量：9
6文晓萍,何滨.NC方案结合中医治疗晚期非小细胞肺癌90例临床观察[J].中医药导报,2013,19(9):21-23. 被引量：11
7林丽珠,陶志广,周岱翰.WHO标准和RECIST在肺癌多中心疗效评价的比较[J].中国肿瘤临床,2006,33(5):253-255. 被引量：41
8刘敏,张璐,孙丽华,柏和,樊文竹.辽宁省肿瘤化疗患者KPS评分情况分析[J].中国肿瘤,2013,22(8):635-637. 被引量：111

二级参考文献48

1陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量：34
2Schiller J H, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].N Engl J Med, 2002,346 (2), 92-98. 被引量：1
3Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non- small cell lung cancer: results from a randomized, plaeebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005,366(9496) : 1527-1537. 被引量：1
4Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial INTACT 1[J].Clin Oncoh2004,22(5): 777-784. 被引量：1
5Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase Ⅲ trial INTACT 2[J]. Clin Oncol, 2(}04,22(5) : 785-794. 被引量：1
6Dancey J ,Shepherd FA, Gralla RJ, et al. Quality of life assessment of second line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase Ⅲ trial [J]. Lung Cancer,2004,43(2) : 183-194. 被引量：1
7Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non- small-cell lung cancer previously treated with chemotherapy [J]. J Clin Oncol, 2004,22(9) : 1589 -1597. 被引量：1
8Lynch T J, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer gefitinib[J]. N Engl J Med, 2004,350(21) :2129-2139. 被引量：1
9Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J]. Clin Cancer Res, 2004,10(24):8195 -8203. 被引量：1
10Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Clin Oncol, 2004,22 (6) : 1103-1109. 被引量：1